IL-11 blockade antibody

An IL-11 blockade antibody is a therapeutic monoclonal antibody designed to target and inhibit interleukin-11 (IL-11) signaling, either by binding directly to the IL-11 ligand or its receptor subunit IL-11Rα. IL-11 is a key pro-fibrotic and pro-inflammatory cytokine implicated in the pathogenesis of chronic inflammatory and fibrotic diseases across multiple organs, including the lungs, kidneys, liver, and skin, as well as in tumor progression. By blocking the interaction of IL-11 with its receptor complex (IL-11/IL-11Rα/gp130), these antibodies inhibit downstream JAK/STAT3, ERK, and PI3K/Akt signaling pathways. This blockade attenuates fibroblast activation, extracellular matrix deposition, and tissue fibrosis, making it a promising therapeutic strategy for conditions such as idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD), pathological scarring, and advanced malignancies.

Other names

anti-IL-11 antibodyanti-IL11 antibodyanti-IL 11 antibodyanti-IL-11 monoclonal antibodyanti-IL11 monoclonal antibodyanti-IL 11 monoclonal antibodyIL-11 inhibitor antibodyIL11 inhibitor antibodyIL 11 inhibitor antibodyIL-11 neutralizing antibodyIL11 neutralizing antibodyIL 11 neutralizing antibody